MIAMI - Veru Inc. (NASDAQ: NASDAQ:VERU), a biopharmaceutical company in the late clinical stage, announced today the appointment of Dr. Louis Aronne as Chief Medical Advisor and member of the Scientific Advisory Board.
Dr. Aronne is a recognized authority in obesity treatment and will contribute to the development of enobosarm, a selective androgen receptor modulator (SARM) aimed at high-quality weight loss by preserving muscle mass.
Enobosarm, in combination with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug, is expected to enhance fat loss while avoiding muscle loss, potentially leading to improved long-term weight maintenance and fewer side effects. The Phase 2b clinical trial of enobosarm is set to begin in April 2024, with results anticipated by the end of the year. A subsequent extension trial will investigate the drug's ability to maintain muscle mass after discontinuing GLP-1 RA treatment, with findings expected in the second quarter of 2025.
Dr. Aronne's extensive background includes over 65 trials on obesity treatments and more than 150 publications. He is the Sanford I. Weill Professor of Metabolic Research and director of the Comprehensive Weight Control Center at Weill Cornell Medicine. His involvement with Veru Inc. aligns with the company's focus on addressing sarcopenic obesity, a condition affecting a considerable portion of older adults with obesity in the United States.
Sarcopenic obesity is characterized by a critical loss of muscle mass, which can lead to various health issues, including frailty. Enobosarm has been studied in 27 clinical trials involving 1,581 participants and has shown to be well-tolerated with no increase in gastrointestinal side effects.
Veru Inc. is also developing sabizabulin, a microtubule disruptor, for the treatment of ARDS in hospitalized patients, and has an FDA-approved product, the FC2 Female Condom®, for dual protection against unplanned pregnancy and sexually transmitted infections.
The company aims to transform into a late-stage biopharmaceutical entity focusing on metabolic diseases, oncology, and ARDS. This press release is based on a press release statement from Veru Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.